DRI Healthcare Trust (TSE:DHT.UN) Price Target Raised to C$23.50 at Raymond James Financial

DRI Healthcare Trust (TSE:DHT.UN) had its target price upped by equities research analysts at Raymond James Financial from C$22.50 to C$23.50 in a research report issued on Monday,BayStreet.CA reports. The firm presently has a “strong-buy” rating on the stock. Raymond James Financial’s target price suggests a potential upside of 27.72% from the stock’s current price.

A number of other equities analysts also recently commented on DHT.UN. Stifel Nicolaus raised their price objective on DRI Healthcare Trust from C$22.00 to C$23.00 and gave the stock a “buy” rating in a report on Tuesday, May 19th. National Bank Financial lifted their price target on shares of DRI Healthcare Trust from C$22.50 to C$23.50 and gave the company an “outperform” rating in a research report on Tuesday, May 19th. Finally, Scotiabank boosted their price objective on shares of DRI Healthcare Trust from C$25.00 to C$30.00 and gave the stock a “sector outperform” rating in a research note on Tuesday, May 19th. One research analyst has rated the stock with a Strong Buy rating and three have assigned a Buy rating to the stock. According to data from MarketBeat.com, DRI Healthcare Trust currently has a consensus rating of “Buy” and an average price target of C$25.00.

DRI Healthcare Trust Stock Performance

TSE DHT.UN traded up C$0.95 during trading hours on Monday, hitting C$18.40. 62,056 shares of the company’s stock were exchanged, compared to its average volume of 59,156. The business’s 50 day moving average is C$17.13 and its 200-day moving average is C$16.63. DRI Healthcare Trust has a 12-month low of C$13.20 and a 12-month high of C$19.04. The firm has a market capitalization of C$1.01 billion, a P/E ratio of -20.44 and a beta of 0.47.

About DRI Healthcare Trust

DRI Healthcare Trust is managed by DRI Capital Inc DRI a pioneer in global pharmaceutical royalty monetization. We provide uniquely favorable exposure for investors in the biopharma industry managing a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world and aiming to acquire dependable patent-protected cash flow streams derived from the sales of those important drugs while limiting the risks and costs connected to drug development. DRI has developed a disciplined strategy predicated on actively sourcing royalty streams on medically necessary products and proudly work with multiple repeat deal partners.DRI Healthcare Trust is an unincorporated open-ended trust governed by the laws of the Province of Ontario pursuant to a declaration of trust dated October 21 2020 as amended.DRI Healthcare Trusts units are listed and trade on the Toronto Stock Exchange under DHT.UN in Canadian dollars and under DHT.U in U.S.